ABOUT
About The 5 Cs of Biotech Investing™
CHARISMA
What does the company do? How exciting are the prospects of the company based on the science, the platform, or the drug candidates at the current stage of development and the competitive position? JNap has the clinical research experience and relevant educational background to analyze biopharma fundamentals. This is where JNap's 30+ years of biopharma investing experience really pays off for subscribers.
CREDIBILITY
How good is the management team and what have they done (or not done) in the past that leads Bio5C to believe (or not believe) they can execute in the future? JNap regularly attends investment conferences and has established relationships with dozens of management teams, KOL's, and professional sell-side and buy-side investors to help provide detailed insight into this often-overlooked factor in biopharma investing.
CATALYSTS
What are the primary catalysts on the horizon that will drive the shares higher or lower? When will these events occur? JNap regularly speaks with partners (trading services, professional investors, etc.) to stay on top of important events. We use social media monitoring and investor presentations to keep our catalyst database current.
CASH/CAPITAL STRUCTURE
How much cash does the company have and how long will it last? When is the last time they've raised cash? When do we project that the company will raise cash again? JNap has a master's degree in finance and relevant industry credentials to perform detailed financial analysis for subscribers. In terms of the financial structure (Cap Table) of the company, JNap asks, "What is the true valuation for the company based on the fully-diluted share count, and are there toxic financial instruments that will limit upside or act as an anchor to drag the stock price performance down despite positive fundamental attributes?" JNap has experience at an investment bank and understands the difference between good and bad financings, and how stock options, warrants, convertible debt, and high-interest loans can negatively affect stock prices.
COMMERCIAL
This is where Bio5C asks, "How large is this opportunity and how successful do we believe the company will be in penetrating the TAM (total addressable market)?" Simply put, JNap examines the opportunity and asks, "Is this company going to make a lot of money or are they just wasting their time?!!"
About JASON NAPODANO
Bio5c was founded by Jason Napodano ("JNap") in March of 2017.
Jason has significant experience as a pharmaceutical and biotechnology stock analyst, starting his career as a laboratory technician in 1995 at the Franlin Biotechnology Center in Blacksburg, VA. Jason moved to a research lab position with TechLab, Inc. in 1996 after graduating from Virginia Tech with a Bachelor of Science in Biochemistry.
In 2000, Jason earned his Masters of Business Administration (MBA) from Wake Forest University with a concentration in Finance, Securities Analysis, and Portfolio Management. Jason worked for Eastover Capital Management, a Charlotte, NC-based money management firm with $450 million in peak assets, starting in 1999 as Vice President and Senior Analyst.
In 2002, Jason earned the Chartered Financial Analyst (CFA) designation (revoked in 2017). In 2003, Jason joined Zacks Investment Research as the firm's Senior Pharmaceuticals Analyst. In 2009, Jason was promoted to Managing Director of Zacks Small-Cap Research, which produced sponsored research on hundreds of small-cap names in the healthcare sector.
Jason left Zacks in 2015 to form BioNap, Inc., an investor intelligence and strategic advisory firm helping small biopharmaceutical companies with investor relations and business development activities. Bio5C started in March 2017 and has been Jason's main focus ever since.